In the course of a clinical trial of acedapsone therapy in 17 patients with lepromatous leprosy, the rate of response to therapy was measured by inoculation of mice with Mycobacterium leprae recovered from biopsy specimens of skin lesions obtained before treatment and at intervals of 4, 12, and 24 weeks after institution oftreatment. The susceptibility ofeach isolate ofM. leprae to dapsone (4,4'-diazninodiphenylsulfone [DDS]) was measured by passaging organisms that had multiplied in mice to new groups of untreated mice and to mice treated with DDS incorporated in the mouse chow in concentrations of 10-5, 3 x 10-5, and 10-4 gIlOO ml. The rate of response to acedapsone therapy and the susceptibility of patient strains of M. leprae to DDS varied widely among patients.
In the course of a clinical trial of acedapsone therapy in 17 patients with lepromatous leprosy, the rate of response to therapy was measured by inoculation of mice with Mycobacterium leprae recovered from biopsy specimens of skin lesions obtained before treatment and at intervals of 4, 12, and 24 weeks after institution oftreatment. The susceptibility ofeach isolate ofM. leprae to dapsone (4,4'-diazninodiphenylsulfone [DDS] ) was measured by passaging organisms that had multiplied in mice to new groups of untreated mice and to mice treated with DDS incorporated in the mouse chow in concentrations of 10-5, 3 x 10-5, and 10-4 gIlOO ml. The rate of response to acedapsone therapy and the susceptibility of patient strains of M. leprae to DDS varied widely among patients.
All isolates were inhibited from multiplication by treatment of mice with 10-4 g of DDS per 100 ml; all-but two isolates were susceptible to 3 x 10-5 g of DDS per 100 ml; and 17 of 36 isolates, representing nine patient strains, were susceptible to 10-5 g of DDS per 100 ml. Plasma levels of DDS measured in the mice administered these diets show that the minimal inhibitory concentration of DDS for M. leprae isolated from untreated patients is about 3 ng/ml. No relationship could be demonstrated between DDS susceptibility of pretreatment isolates i M. leprae and the rate at which patients responded to acedapsone therapy. Neither acedapsone treatment of patients nor DDS treatment of mice appeared to select genotypically more resistant M. leprae. Acedapsone (4,4'-diacetamidodiphenylsulfone [DADDS] ) is a relatively insoluble derivative of dapsone (4,4'-diaminodiphenylsulfone [DDS] ) which produces a prolonged low plasma level of DDS after intramuscular administration (3) . First developed for use in malaria chemoprophylaxis (27) , DADDS was found to be effective against Mycobacterium leprae in footpad infection in mice (16) and in patients with lepromatous leprosy (21, 25) , to whom the drug was administered .intramuscularly at a dosage of 225 mg every 11 weeks. This dosage of DADDS yielded a maximal plasma DDS concentration of 50 to 80 ng/ml 1 to 5 weeks after the dose; plasma DDS levels fell to a minimum of 30 to 60 ng/ml 11 weeks after the dose (10, 13) . Even these low levels of DDS would be expected to produce a chemotherapeutic result, because they are substantially higher than the minimal inhibitory concentration of DDS for M.
leprae. This has been established at less than 10 ng/ml of plasma in studies with mice (2, 10) and rats (11) infected with M. leprae. However, the DDS levels obtained after DADDS administration are much lower than the maximal levels of 2,000 ng/ml of plasma found in patients receiving oral doses of 100 mg of DDS (11) .
A trial of DADDS therapy in 10 patients with previously untreated lepromatous leprosy showed that, in terms of the rate of killing of M. leprae, three patients responded as rapidly and seven patients responded more slowly than did patients receiving 50 mg of DDS daily (21) . The' staging of a trial of DADDS therapy in Cebu, the Philippines, among patients with previously untreated lepromatous leprosy provided the opportunity for a prospective study of possible determinants of the rate of response of patients during treatment with DADDS. ( Rate of response to DADDS. The response of patients with lepromatous leprosy to treatment with DADDS was measured both in Cebu and in San Francisco in terms of the rate at which M. leprae were killed, i.e., rendered noninfectious for mice, during therapy. This procedure has been described previously (6, 19, (21) (22) (23) 27) . In brief, all pretreatment specimens contained organisms infectious for mice; this was a prerequisite for admitting patients to the trial. In terms of their response to therapy, the patients may be divided into four groups. (i) Group 1 includes patients no. 1, 5, 11, and 37; no multiplication of M. leprae occurred in mice inoculated with organisms recovered from any of the skin biopsy specimens obtained 4, 12, or 24 Measurement of susceptibility to DDS. The technique for measuring the susceptibility of strains of M. Ieprae to DDS was a combination of Shepard's "continuous" and "kinetic" methods (18) . When M. leprae inoculated in our laboratory were found to have multiplied in mice, a passage was made of 5 x 103 organisms into each hind footpad of 60 locally bred male BALB/c mice, divided into four groups of 15. One of the groups was left untreated; the other three groups received chow containing DDS in concentrations of 10-5, 3 x 10-5, and 10-4 g/100 ml for about 150 days, beginning on the day of inoculation.
Both the diets and water were allowed ad libitum.
Harvests of M. leprae were made from pools of four footpads of the untreated mice about 100 and again about 120 days after inoculation. Just before drug administration was stopped, organisms were harvested from pools of eight footpads of the treated mice; additional harvests were made from the treated mice at intervals thereafter. The methods by which mouse tissues were processed and the mice were inoculated and harvested have been described previously (15, 24) .
Monitoring DDS dosage to mice. The DDS-containing chow was prepared by the addition of appropriate quantities of a 1% solution of DDS (K & K Laboratories, Inc., Hollywood, Calif.) in 95% ethanol to 5-kg batches of commercially prepared mouse meal (Wayne Lab-Blox, Allied Mills, Inc., Chicago, Ill.) in a liquid-solid twin-shell blender (PattersonKelly Co., East Stroudsburg, Pa.). Drug-containing mouse chow was stored at 4 C. At first, the dosages of DDS to the mice were monitored by three means. Firstly, each batch of DDS-containing diet was sampled at the time of preparation; these samples were frozen and stored at -70 C for later analysis. Secondly, at the time of the 150-day harvest of M. leprae from DDS-treated mice, samples of the diets were removed from the cages and stored frozen. And thirdly, the four mice killed for each 150-day harvest were bled by heart puncture, and the heparinized plasma was separated, pooled, and stored frozen for later analysis. For the greater part of this study, DDS dosage to the mice was monitored by means of the plasma levels of DDS.
Levels of DDS in plasma were determined by a chromatographic-fluorometric technique (9) which was recently modified (8) to obtain a sensitivity of 0.1 ng of DDS per ml of plasma. Levels of DDS in diets were determined colorimetrically after double extraction by using a modification (14) of the method of Bratton and Marshall (1) . DDS was extracted from 10-g portions of the powdered diets by shaking with 100 ml of 1 N HCI. After removal of the insoluble material by centrifugation, 75 ml of the acid extract was neutralized with 8 ml of ice-cold 10 N NaOH, and the mixture was extracted with 25 ml of ethylene dichloride. After phase separation by centrifugation, the upper aqueous layer was removed by aspiration. The organic phase was then washed twice with 5 ml of 0.1 N NaOH, removing the aqueous phase each time after shaking and centrifugation to separate the phases. Finally, the DDS was extracted from 20 ml of the ethylene dichloride solution into 1.5 ml of 2 N HCI, and 1.0 ml of the acid extract was diazotized and coupled. The practical limit of sensitivity was 1,000 ng of DDS/10 g of diet, which corresponds to a diet containing 10-5 g of DDS per 100 ml. The extractability of DDS from diets was the same as from water. All assays were performed in duplicate; the variability in the procedure was ±2.1%. RESULTS Dosage of DDS. As a preliminary study, DDS concentrations were measured during the first 3 months of this study in the batches of mouse chow as prepared, in the chow recovered from the mouse cages at the time mice were sacrificed for the 150-day harvests, and in the plasma of the mice sacrificed for harvests. The results of these analyses, summarized in the second, third, and fourth columns of Table  1 , show that the concentrations of DDS in the mouse chow recovered from the cages averaged 60 to 100%o of expected, whereas the average concentration measured in the batches of prepared diets was that expected. The relationship of plasma levels of DDS in mice to the concen- trations of DDS measured in the batches of prepared diets and found in the mouse chow recovered from the cages was examined by a linear regression technique (4) . The results are shown in the footnotes to Table 1 , in which the regression equations are presented in the form: y = y + (b + to.05SD)(x -i). The regression of log1o plasma DDS level (y) on log1O DDS concentration in the chow recovered from the mouse cages (x) was parallel to that of log1o plasma DDS level on log1O DDS concentration in the batches of prepared diets, but significantly different from it except at x = -4.0 (dietary concentration, 10-4 g/100 ml).
A number of studies directed toward ascertaining the explanation for the uniformly decreased levels of DDS in the samples of mouse chow recovered from the cages yielded inconsistent results. We found no evidence that the DDS concentrations declined with storage of the diets at 4 C. Because the powder feeders in the mouse cages were emptied, cleaned, and refilled twice weekly, none of the diets rmained in the cages for longer than 4 days. DDS concentrations did not appear to decrease during this time at room temperature. There was no important variation of DDS concentration from batch to batch. The dosage of DDS to the mice was therefore monitored by measurement of plasma DDS levels.
Analysis of the DDS concentration of 110 plasma samples obtained from mice sacrificed for the 150-day harvests yielded values that were not different from the plasma levels found in the preliminary study (column 4, Table 1 ). The linear regression of log10 plasma DDS concentration on log10 DDS concentration measured in the batches of mouse chow as prepared compares well with that calculated from the data summarized by Ellard et al. (2), as shown by the plots in Fig. 1 .
The variation of the plasma concentrations of DDS from month to month during the current study is shown in Fig. 2 . Although the plasma DDS concentrations may be noted to vary within the range -50% and + 100%o of the mean, no trend with time is discernible. There is virtually no overlap of plasma DDS concentrations between the groups of mice receiving different dosages of DDS.
Susceptibility of M. Ieprae to DDS. The susceptibility to DDS of 17 pretreatment isolates ofM. leprae was measured in mice treated with 10-5, 3 x 10-5, or 10-4 g of DDS per 100 ml. The method by which the effects of DDS treatment on bacterial multiplication were used to evaluate susceptibility to DDS is exemplified by the results of studies in patients no. 5 (a patient from group 1, organisms noninfective for mice after only 4 weeks of treatment with DADDS) and no. 29 (a group 3 patient, organisms multiplied in mice after 4 and 12 weeks of DADDS treatment but not after 24 weeks). These results are presented in graphic form in Fig. 3 . The organisms isolated from the pretreatment biopsy specimen of patient no. 5 had multiplied to the level of 105-" acid-fast bacilli 5's organisms were susceptible to 10-4 and 3 x 10-5 g of DDS but not to 10-s g of DDS per 100 ml. The M. leprae isolated from the pretreatment specimen of patient no. 29 proved more susceptible to DDS. These had multiplied to the level of 106/footpad in untreated mice by day 150, the day drug administration was stopped, whereas no multiplication was found in the mice fed any of the DDS-containing diets.
The susceptibility of an organism to the action of an antimicrobial drug is traditionally measured in terms of the ability of the drug to inhibit multiplication ofthe organism. The data presented in Fig. 3 suggest a second criterion of susceptibility. When multiplication ofM. leprae has been inhibited during administration of a drug, multiplication of the organisms may resume immediately after the cessation of drug treatment, or only after some delay longer than can be accounted for by the presence of effective concentrations of the drug in the mouse, or not at all. Once treatment has been withdrawn, multiplication ofM. leprae will resume immediately if the effect of the drug is primarily bacteriostatic, whereas no multiplication may occur if the drug has exerted a bactericidal effect. A delay between cessation of treatment and resumption of multiplication may result from killing of a portion of the inoculum, with only the surviving fraction giving rise to later multiplication. Alternatively, delayed multiplication may represent prolonged bacteriostasis, with later multiplication arising from the entire bacterial population (5) . Shepard has shown (17) that the duration of the delay is proportional to the dosage of DDS, suggesting that the delay between cessation of DDS treatment of mice and resumption of multiplication of M. leprae may represent a useful criterion of susceptibility of the organism to the drug.
In Fig. 3 , multiplication of M. leprae may be noted to have resumed without delay in the case oftwo growth curves, that of patient no. 5's organisms in mice treated with 3 x 10-5 g of DDS per 100 ml and that of patient no. 29's organisms in mice treated with 10-5 g of DDS per 100 ml, whereas multiplication resumed only after some delay in both groups of mice treated with 10-4 g of DDS per 100 ml and in mice infected with organisms from patient no. Multiplication of patient no. 5's organisms may be noted to have begun without apparent delay when treatment with 3 x 10-5 g of DDS per 100 ml was stopped. On the other hand, multiplication after cessation of treatment with 10-4 g of DDS per 100 ml began only after a delay of 91 days. Harvests of M. leprae isolated from the pretreatment biopsy specimen of patient no. 29 showed that multiplication began without delay once treatment with 10-5 g of DDS per 100 ml was stopped, whereas there was a delay of 37 days after treatment with 3 x 10-$ g of DDS per 100 ml was stopped before multiplication of M. leprae began; and multiplication was delayed for 52 days after stopping treatment with 10-4 g of DDS per 100 ml. These results suggest that the susceptibility of an isolate ofM. leprae to DDS might be characterized both by the level to which the organisms had multiplied during treatment with a given dosage of DDS and by the duration of delay between cessation of treatment and resumption of multiplication.
The results of the studies of DDS susceptibility and the relationship between the rate at which patients responded to DADDS and the susceptibility of patient strains of M. leprae to DDS are summarized in footpad by treatment of mice with 10-5 g of DDS per 100 ml; these strains may be considered susceptible to this dosage. On the other hand, M. leprae of two patient strains multiplied at least 20-fold (i.e., to 105 organisms/footpad) but less than 100-fold (i.e., <5 x 105 organisms/footpad) during treatment of mice with 10-5 g of DDS per 100 ml (column 4); these strains may be considered partially susceptible. Finally, the organisms of seven strains (also column 4) underwent at least 100-fold multiplication from the standard inoculum of 5 x 103 org'anisms/footpad during administration of the DDS in the smallest dosage. The organisms of only two patient strains demonstrated greater than 20-fold but less than 100-fold mulitiplication during treatment with 3 x 10-5 g of DDS per 100 ml, indicating partial susceptibility to this dosage of DDS. As already noted, the organisms of all patient strains were susceptible to DDS administered in a dosage of 10-4 g/100 ml. The number of M. leprae per footpad in the harvests performed from the pooled tissues of eight footpads just before stopping the 150-day course of treatment with 10-5 g of DDS per 100 ml appears to be a useful criterion of susceptibility, because it discriminates between more and less susceptible strains of M. leprae. However, criteria based on the multiplication of M. leprae during treatment with the two larger dosages of DDS would not be useful, and a more discriminating criterion is needed. Columns 9 and 10 of Table 2 show that the resumption ofmultiplication ofM. leprae from no specimen was delayed as long as 30 days after cessation of treatment with 10-5 g of DDS per 100 ml. On the other hand, as shown in the last four columns of this table, the time between cessation of treatment with 3 x 10-5 g ofDDS per 100 ml and resumption ofmultiplication was found to vary among the patient strains and represents, therefore, a more discriminating criterion. The results of treatment of mice with 10-4 g of DDS per 100 ml are too uniform to be useful in distinguishing more susceptible from more resistant strains of M.
leprae.
The measurements of susceptibility to DDS produced results that appear internally consistent. There was good correspondence between the two criteria of susceptibility to DDS, the number of organisms per footpad at the end of the period of administration of 10-5 g of DDS per 100 ml and the duration of the delay before multiplication ofM. leprae began after cessation of administration of 3 x 10-5 g of DDS per 100 ml (Table 2 ). Only one of eight isolates multiplying to a level lower than 105 acid-fast bacilli/ footpad during treatment with 10-5 g of DDS per 100 ml (an isolate from a group 2 patient) multiplied with a delay shorter than 30 days after withdrawal of 3 x 10-5 g of DDS per 100 ml, whereas seven of nine isolates multiplying to a level of at least 105 acid-fast bacilli/footpad during treatment with 10-5 g of DDS per 100 ml began to multiply within 30 days after cessation of treatment with 3 x 10-5 g of DDS per 100 ml. The probability that this distribution could have been encountered by chance is less than 0.015 (4) .
The four most rapidly responding patients (those of group 1) appear to harbor some of the least susceptible strains, whereas one of the two most slowly responding patients (from group 4) harbored a strain of M. leprae that proved quite susceptible to DDS by both criteria (Table 2 ). There appears, therefore, to be no relationship between the rate of response of patients to treatment with DADDS and the susceptibility of the patient strains of M. leprae to DDS in mice. Alternative explanations of the variation of the rate ofresponse among patients will be considered below.
Change of DDS susceptibility during DADDS treatment. This study provided an opportunity to examine the effect of treatment on the susceptibility to DDS of the M. leprae that survived treatment. Nineteen isolates of M. leprae were obtained 4, 12, or 24 weeks after beginning DDS treatment of the 13 patients in groups 2, 3, and 4. These specimens are identified in Table 3 . The tests of DDS susceptibility were carried out only on M. leprae isolated in San Francisco, whereas measurement of the rate of response to DADDS was based on isolations of M. leprae both in Cebu and in San Francisco; therefore, the number of post-treatment isolates tested is sometimes smaller than the number of patients.
The susceptibility to DDS of the 19 isolates of M. leprae recovered during DADDS treatment of the 13 group 2, 3, and 4 patients was measured. In Table 4 , the susceptibility of each posttreatment isolate is compared with that of the corresponding pretreatment isolate at each dietary level of DDS. The pretreatment isolates have been pooled without regard for the patients' response group. The post-treatment isolates have also been pooled without regard for the patient group and without attempting to distinguish among multiple isolates from the same patient. The M. leprae isolated before treatment from eight of the 13 patients multiplied less than 20-fold (to <105/footpad) during treatment of mice with 10-5 g of DDS per 100 ml (Table 4) . Twelve isolates were made from these patients during DADDS treatment, of which eight multiplied to <105 M. keprae/footpad and four to at least 105 organisms/footpad during treatment of mice with 10-5 g of DDS per 100 ml. The pretreatment isolates from five patients multiplied at least 20-fold during treatment of mice with 10-5 g of DDS per 100 ml; of the seven post-treatment isolates from these patients, only one multiplied less than 20-fold during treatment of mice with the same concentration of DDS. The probability that this distribution of post-treatment isolates could have occurred by chance is <0.05 (4). Thus, post-treatment isolates of M. keprae were likely to exhibit the same degree of susceptibility to DDS as did the corresponding pretreatment isolates.
The susceptibility ofM. leprae isolated before and during DADDS treatment to 3 x 10-5 g of DDS per 100 ml is compared in terms of the duration of the delay between withdrawing DDS treatment of the mice and the resumption of multiplication of M. keprae (Table 4) . Here, too, the patients whose pretreatment isolates were more susceptible to DDS (delay ;s30 days) were likely to have more susceptible organisms isolated during treatment. The likelihood that this distribution ofpost-treatment isolates ofM. leprae could have occurred by chance is smaller than 0.01. As was the case with the pretreatment isolates of M. leprae, the M. leprae isolated during DADDS treatment were almost uniformly susceptible to 10-4 g of DDS per 100 ml in the mouse diet (Table 4) .
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In summary, there was no striking or consistent change of DDS susceptibility ofM. leprae during treatment of patients with DADDS. Certainly, no progressive change of DDS susceptibility was seen in the specimens from patients yielding more than one isolation of M. leprae during treatment with DADDS.
This study also provided an opportunity to retest the susceptibility to DDS of M. leprae that had been inhibited from multiplication during treatment of mice with DDS. Four strains of M. leprae from a patient from each response group, two of them pretreatment isolates and two isolates recovered after 4 weeks of DADDS treatment, were reisolated from DDS-treated mice after DDS treatment of the mice had been terminated and the organisms had resumed multiplication.
In Table 5 , the susceptibility of the reisolated M. leprae is compared with that measured in the original test at each dietary level of DDS. Organisms that had multiplied after cessation of treatment of mice with 10-4 g of DDS per 100 ml (the strain of patient no. 5), for example, were as susceptible to DDS as the original isolate. The results of this study (Table 5) In a second experiment, mice were inoculated with the same strain of M. leprae, and 10-1 g of DDS per 100 ml was administered for 90 days beginning 60 days after inoculation. By day 322, the organisms were found to have multiplied and were harvested and passaged twice through untreated mice. Multiplication of the organisms in the third serial passage was inhibited by treatment of the mice with 10-4 g of DDS per 100 ml. Thus, treatment of mice with DDS did not appear to select genotypically more resistant strains of M. leprae.
DISCUSSION
In an earlier study (20) , it was shown that M. leprae isolated from previously untreated patients with lepromatous leprosy were inhibited from multiplying in mice by administration to the mice of a diet containing 10-4 g of DDS per 100 ml. Some isolates were found to be inhibited by DDS administered in a concentration of 10-5 g/100 ml. The current study was carried out to learn if differences of DDS susceptibility among patient strains of M. leprae, all susceptible to 10-4 g of DDS per 100 ml, might explain differences of the rate at which M. leprae are killed during DADDS therapy of patients with previously untreated lepromatous leprosy.
The technique by which the susceptibility of strains ofM. leprae to DDS was measured in the current study was a combination of Shepard's "continuous" and "kinetic" methods (18) . In the continuous method, mice are treated from the day of inoculation, whereas in the kinetic method treatment is begun only after the beginning of logarithmic multiplication. The continuous method is, therefore, a more sensitive test. Because it requires the cessation of therapy after multiplication of the organisms in untreated mice has reached its maximum, the kinetic method permits a distinction between merely bacteriostatic and bactericidal activity. The use of the combined technique in this study provided two criteria by which the susceptibility to DDS of each strain could be evaluated. Beginning treatment on the day of inoculation amplified the effects of the smallest dosage of DDS. Because virtually all of the isolates were inhibited from multiplication by treatment of mice with the two larger dosages, use of the continuous method alone would have provided very little additional information. Withdrawal of treatment after about 150 days, on the other hand, permitted the distinction of degrees of susceptibility to the larger dosages of DDS.
Pretreatment isolates of M. leprae from the 17 patients in this study were all inhibited from multiplication by the administration to mice of 10-4 g of DDS per 100 ml. The susceptibility of the 17 patient strains of M. leprae to smaller concentrations of DDS was found to vary over a 10-fold range: eight strains were susceptible to 10-5 g of DDS per 100 ml; two strains were partially susceptible to 10-5 g of DDS per 100 ml and fully susceptible to 3 x 10-5 g of DDS per 100 ml; five strains were resistant to 10-5 g of DDS per 100 ml and fully susceptible to 3 x 10-5 g of DDS per 100 ml; and two strains were resistant to 10-5 g of DDS per 100 ml and partially susceptible to 3 x 10-5 g of DDS per 100 ml.
A by-product ofthis study is the measurement of the minimal inhibitory concentration of DDS for 17 strains of M. leprae from previously untreated patients. The mean plasma concentration of DDS obtained by administering 3 x 10-5 g of DDS per 100 ml in the mouse chow may be noted in Table 1 to be slightly smaller than 3 ng of DDS per ml. Because 15 of the 17 patient strains of M. leprae were susceptible to this plasma concentration of DDS, the results of this study confirm earlier estimates of the minimal inhibitory concentration of DDS for M. leprae (1 to 10 ng/ml in the mouse [2, 10] , and 1.5 to 4 ng/ml in the rat [11] ).
The rate at which M. leprae were rendered noninfective for mice during treatment of these 17 patients with DADDS varied as much in this study as in an earlier trial of DADDS treatment of patients with previously untreated lepromatous leprosy (21) . No correlation co4ld be found, however, between the rate at which M. leprae were killed during DADDS treatment of patients and the susceptibility of the organisms to DDS in mice. (12) . An explanation is implicit in the description by Mitchison of studies in tuberculosis (7) . These studies suggested that M. tuberculosis in stationary phase were more resistant to mild heat treatment (53 C for 60 min) than were organisms tested during logarithmic multiplication, and that tuberculosis patients whose sputum contained organisms more susceptible to heat treatment responded more rapidly to isoniazid than did patients whose sputum contained heat-resistant organisms. The technique by which the rate of response to DADDS was measured required repeated biopsies from the same lesion. All of the lesions in a patient with lepromatous leprosy do not appear to evolve at the same rate, some having been established for some time and others having only recently appeared at the time that the patient presents for treatment. It may well be that the rate of response truly measures the rate at which M. leprae are killed in a given lesion rather than in the patient as a whole, and that the response will be more rapid when new lesions (organisms in logarithmic phase) are sampled and less rapid when old lesions (organisms in stationary phase) are biopsied. Because the organisms obtained from one lesion are very likely genotypically identical with those of any other lesion of the same patient, one should not expect a good correlation between the susceptibility of the strain of M. leprae to DDS and the rate at which the organisms in a given lesion are killed during effective antimicrobial therapy.
That the M. leprae of a particular patient are genotypically identical is suggested by the results of the studies of DDS susceptibility after some period of DADDS therapy, or after passage through DDS-treated mice. An obvious shortcoming of the study of changes of DDS susceptibility during DADDS therapy is that the most complete information will become available from those patients who respond most slowly, whereas no organisms can be isolated for measurement of DDS susceptibility once DADDS therapy of the most rapidly responding patients has begun. Nevertheless, a comparison of the DDS susceptibility of isolates obtained later during DADDS therapy with that of the pretreatment isolates suggests that DADDS therapy does not select genotypically more resistant individuals in the bacterial population. The studies of the organisms recovered from DDS-treated mice yielded similar results. These results say nothing about DDSresistant M. leprae (i.e., organisms that multiply in mice treated with 10-4 g of DDS per 100 ml), which are undoubtedly present in the untreated patient with lepromatous leprosy but in such small numbers that they are unlikely to be encountered among the small numbers of M. leprae recovered from skin biopsy specimens and inoculated into mice.
